Abstract
Pain in patients with impaired renal function may be a significant problem requiring treatment with opioids. However, pharmacokinetic and metabolic changes associated with an impaired renal function may raise some concerns about side effects and overdosing associated with opioid agents in this patients population. In order to give recommendations on this issue, we review the available evidences on the pharmacokinetics and side effects of most common opioids used to treat pain. The results of this review show that the half-life of the parent opioid compounds and of their metabolites is increased in the presence of renal dysfunction, for which careful monitoring of the patient, dose reduction and a longer time interval between doses are recommended. Among opioids, morphine and codeine used with great caution and possibly avoided in renal failure/dialysis patients; tramadol, hydromorphone and oxycodone can be used with caution and close patients monitoring, whereas transdermal buprenorphine, methadone and fentanyl/sufentanil appear to be safe to use in patients with renal failure.
Keywords: Analgesia, analgesics, buprenorphine, dialysis kidney, morphine, opioids, oxycodone, pain, renal failure
Current Drug Targets
Title: The Use of Major Analgesics in Patients with Renal Dysfunction
Volume: 11 Issue: 6
Author(s): Pasquale Niscola, Laura Scaramucci, Gisella Vischini, Marco Giovannini, Michele Ferrannini, Pasquale Massa, Paola Tatangelo, Massimo Galletti and Roberto Palumbo
Affiliation:
Keywords: Analgesia, analgesics, buprenorphine, dialysis kidney, morphine, opioids, oxycodone, pain, renal failure
Abstract: Pain in patients with impaired renal function may be a significant problem requiring treatment with opioids. However, pharmacokinetic and metabolic changes associated with an impaired renal function may raise some concerns about side effects and overdosing associated with opioid agents in this patients population. In order to give recommendations on this issue, we review the available evidences on the pharmacokinetics and side effects of most common opioids used to treat pain. The results of this review show that the half-life of the parent opioid compounds and of their metabolites is increased in the presence of renal dysfunction, for which careful monitoring of the patient, dose reduction and a longer time interval between doses are recommended. Among opioids, morphine and codeine used with great caution and possibly avoided in renal failure/dialysis patients; tramadol, hydromorphone and oxycodone can be used with caution and close patients monitoring, whereas transdermal buprenorphine, methadone and fentanyl/sufentanil appear to be safe to use in patients with renal failure.
Export Options
About this article
Cite this article as:
Niscola Pasquale, Scaramucci Laura, Vischini Gisella, Giovannini Marco, Ferrannini Michele, Massa Pasquale, Tatangelo Paola, Galletti Massimo and Palumbo Roberto, The Use of Major Analgesics in Patients with Renal Dysfunction, Current Drug Targets 2010; 11 (6) . https://dx.doi.org/10.2174/138945010791170879
DOI https://dx.doi.org/10.2174/138945010791170879 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anorexia Nervosa and the Use of Total Parenteral Nutrition Refeeding
Current Nutrition & Food Science Organic Lesions in the Brain MRI of Children with Febrile Seizure
Current Medical Imaging Postoperative Delirium
Current Drug Targets Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Integrating Pharmacogenetics for Assessment of Herb-Drug Interactions: Has the Time Come?
Current Pharmacogenomics and Personalized Medicine Impact of Sitagliptin on Non-diabetic Covid-19 Patients
Current Molecular Pharmacology CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design NO Signaling Through cGMP in Renal Tissue Fibrosis and Beyond: Key Pathway and Novel Therapeutic Target
Current Medicinal Chemistry Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability
Current Clinical Pharmacology Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Biofunctional Materials for Directing Vascular Development
Current Vascular Pharmacology Recent Patents in the Field of Radioprotector Development: Opportunities and Challenges
Recent Patents on Biotechnology Backbone-Cyclized Peptides: A Critical Review
Current Topics in Medicinal Chemistry β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Genetically Engineered Elastin-based Biomaterials for Biomedical Applications
Current Medicinal Chemistry Toll-Like Receptors and Kidney Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
Current Vascular Pharmacology Refractory Behçet’s Disease with Multi-organ Involvement - Learning from Failure
Current Rheumatology Reviews